Event-Free Survival Benefit of Neoadjuvant Immunotherapy in MIBC

Continuing with his explanation of his recent trial exploring the benefits of neoadjuvant pembrolizumab in patients with muscle-invasive bladder cancer, Roger Li, MD, of the H. Lee Moffitt Cancer Center and Research Institute, highlights the event-free survival outcomes data as well as interesting findings among patients with residual disease in the bladder or lymph nodes.

He concludes with a comment on what further types of research are needed before these findings can warrant practice-changing discussions.

View his previous comments on The Growing Role of Neoadjuvant Immunotherapy in MIBC.